Navigation Links
Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)
Date:2/5/2009

Study Evaluating Cysteamine in Collaboration with UC San Diego

NOVATO, Calif., Feb. 5 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced the completion of patient enrollment in its Phase 2a open-label clinical trial to evaluate cysteamine bitartrate ("cysteamine") in patients diagnosed with non-alcoholic steatohepatitis ("NASH"). NASH, a progressive form of liver disease that accounts for approximately 10% of newly diagnosed cases of chronic liver disease, is one of the leading causes of cirrhosis in the U.S. NASH patients are currently limited to managing their disease through weight control, diet and exercise.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071022/NYM074LOGO )

NASH is believed to affect 2% to 5% of the U.S. population. While commonly diagnosed in insulin-resistant obese adults, NASH can also occur in children, elderly and non-diabetic persons of average weight. Though most people with NASH feel healthy and show no outward signs of liver disease, NASH causes decreased liver function and potentially leads to cirrhosis, liver failure and end-stage liver disease. In more severe cases, the progressive nature of NASH may require liver transplantation in affected patients.

Under a collaboration agreement between the University of California, San Diego ("UC San Diego") and Raptor, UC San Diego is conducting the Phase 2a clinical trial at UC San Diego's General Clinical Research Center. In the six-month, open-label clinical trial, UC San Diego enrolled a total of 12 adolescent NASH patients receiving a twice daily oral dose of cysteamine and will measure possible reduction of blood alanine aminotransferase ("ALT") and aspartate aminotransferase ("AST") levels as a biomarker of cysteamine's efficacy for potentially t
'/>"/>

SOURCE Raptor Pharmaceuticals Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
2. Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire dAngers for Phase II Clinical Trial in Huntingtons Disease
3. Raptor Pharmaceuticals Provides Update on Targeting Platforms
4. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
5. Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease
6. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
7. Raptor Pharmaceuticals Provides Update of Product Programs
8. Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository
9. Alseres Pharmaceuticals Completes Enrollment in First Stage of the Altropane(R) POET-2 Phase III Program
10. Endo Pharmaceuticals and Alexza Pharmaceuticals Conclude Research Collaboration
11. Access Pharmaceuticals Presents new Combination Data on the Companys Angiolix(R) Therapeutic Monoclonal Antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)...  The Alabama Supreme Court, in a 6-3 decision on ... who mislead doctors into believing that prescription medicines the companies ... v. Wyeth, and the decision came after the Supreme Court ... year. Heninger Garrison Davis attorneys Lew Garrison and ... Danny Weeks . The decision won a ...
(Date:8/19/2014)... , Aug. 19, 2014 Research and ... "Pharmaceutical Contract Manufacturing - Global Strategic Business Report" ... analyzes the worldwide markets for Pharmaceutical Contract Manufacturing in ... Vials, and IV solutions), Solid Dosage Forms (Tablets and ... Gels, Creams & Ointments). The report provides ...
(Date:8/19/2014)... 2014  AVIA – a provider-led accelerator that puts ... problems in healthcare ­– announces Sutter Health, a not-for-profit ... as the most recent addition to the AVIA Innovator ... AVIA,s inaugural cohort focused helping patients navigate the healthcare ... a patient,s providers so they work as a larger ...
Breaking Medicine Technology:Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 2Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 3Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 4Global Pharmaceutical Contract Manufacturing - Strategic Business Report 2014 2AVIA and Sutter Health Join Forces to Address Healthcare's Most Pressing Challenges 2
... measurement technology, today announced the addition of the EmBand 24™ to the EmBand™ family of neuromarketing measurement devices. , ... , , ... ... ...
... , ATLANTA , March 22 Fulcrum Ventures announced today that they invested $1.25 ... solution for kit design, production, client supply management and patient specimen tracking.  Based in Columbus, Georgia , ... ... , ...
Cached Medicine Technology:EmSense Announces Release of Revolutionary EmBand 24(TM) 2EmSense Announces Release of Revolutionary EmBand 24(TM) 3EmSense Announces Release of Revolutionary EmBand 24(TM) 4Fulcrum Ventures Leads $1.25 Million Investment in Path-Tec, LLC 2Fulcrum Ventures Leads $1.25 Million Investment in Path-Tec, LLC 3
(Date:8/20/2014)... easier to predict both breast cancer relapses and ... unique gene. The newly found marker could help ... a treatment regimen that is more effective. The ... A*STAR,s Institute of Molecular and Cell Biology (IMCB), ... Singapore) at the National University of Singapore (NUS). ...
(Date:8/20/2014)... It’s no secret that millions of Americans are ... on Drug Abuse, nearly 24 million Americans are using ... is the fact that the total number of users ... in a struggle with substance abuse often feel there ... newly-redesigned AbuseTreatmentCenters.net has released updated lists of substance ...
(Date:8/20/2014)... Mateo, CA (PRWEB) August 20, 2014 ... newest product—the Really Little Green Pouch —to meet ... to feed babies and toddlers homemade foods. , ... Little Green Pouch co-founder Maggie Crawford. She continues, ... kids, to limit exposure to things like pesticides and ...
(Date:8/20/2014)... Botanica Day Spa has ... new and popular stem cell line from Pevonia®, ... wrinkles and naturally repairs the skin. The spa ... service by offering clients a complimentary dermaplaning session ... , Pevonia® continues to be a global leader ...
(Date:8/20/2014)... car at home and getting to work by walking, cycling ... study indicates. Researchers looked at thousands of people in ... and 72 percent of women drove to work, 10 percent ... and 14 percent of men and 17 percent of women ... more and had higher levels of body fat than those ...
Breaking Medicine News(10 mins):Health News:Novel gene predicts both breast cancer relapse and response to chemotherapy 2Health News:Re-Launched AbuseTreatmentCenters.net Offering New List of Substance Abuse Resources 2Health News:Little Green Pouch Launches New Product to Help Health-conscious Parents Reduce Babies’ Eco-footprint 2Health News:New Stem Cell Facial Unveiled at Botanica Day Spa 2Health News:New Stem Cell Facial Unveiled at Botanica Day Spa 3Health News:Want to Stay Slim? Leave the Car at Home 2
... 7 (HealthDay News) -- In November, the U.S. Food and ... the treatment of breast cancer. But, a new study ... with a specific type of aggressive breast tumor when used ... (bevacizumab) had been approved in the United States in 2008 ...
... the fierce national debate over a new federal law ... widely assumed that private health insurance can do a ... U.S. government. But a first-of-its-kind analysis of newly ... comes to infants covered by insurance. Among the ...
... HealthDay Reporter , WEDNESDAY, Dec. 7 (HealthDay News) ... with low-risk prostate cancer, a new draft report released ... concluded that research on the safety of "active surveillance" ... men opt for surgery or other treatments that can ...
... have altered natural bioelectrical communication among cells to directly ... at a particular location within a vertebrate organism. Using ... biologists at Tufts University,s School of Arts and Sciences ... of the head area. The researchers achieved most ...
... California,s low-income seniors with disabilities are struggling to remain in ... and may be slashed even further, according to a new ... with support from The SCAN Foundation. Should ... to In-Home Supportive Services (IHSS) on Dec. 15, as proposed ...
... Amanda Gardner HealthDay Reporter , WEDNESDAY, Dec. 7 ... through strategically placed "seeds" had double the risk of a ... their entire breast, new research finds. This type ... side effects, including infection, according to the study. "We ...
Cached Medicine News:Health News:Avastin Boosted Survival for Type of Aggressive Breast Cancer: Study 2Health News:Public health insurance offers insured infants better, less costly care than private plans 2Health News:Public health insurance offers insured infants better, less costly care than private plans 3Health News:Public health insurance offers insured infants better, less costly care than private plans 4Health News:Public health insurance offers insured infants better, less costly care than private plans 5Health News:Active Surveillance May Benefit Men With Low-Risk Prostate Cancer 2Health News:Researchers discover that changes in bioelectric signals cause tadpoles to grow eyes in back, tail 2Health News:Researchers discover that changes in bioelectric signals cause tadpoles to grow eyes in back, tail 3Health News:Older Californians with disabilities struggle to remain at home as public programs lose funding 2Health News:Older Californians with disabilities struggle to remain at home as public programs lose funding 3Health News:Older Californians with disabilities struggle to remain at home as public programs lose funding 4Health News:Targeted Radiation May Not Be Better for Breast Cancer 2Health News:Targeted Radiation May Not Be Better for Breast Cancer 3